Santen Pharmaceutical (OTCMKTS:SNPHY) Trading Down 4.7% – Here’s What Happened

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) fell 4.7% during mid-day trading on Thursday . The stock traded as low as $11.65 and last traded at $11.65. 788 shares changed hands during trading, a decline of 94% from the average session volume of 13,410 shares. The stock had previously closed at $12.22.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Santen Pharmaceutical currently has a consensus rating of “Hold”.

Santen Pharmaceutical Stock Down 4.7%

The company has a 50 day simple moving average of $11.43 and a two-hundred day simple moving average of $10.97. The company has a market capitalization of $3.75 billion and a P/E ratio of 0.10.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.